In line with this, recently engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages loaded with resiquimod (R848@M2pep-MPsAFP) were developed to target and reprogram M2-like TAMs into M1-like phenotypes to ameliorate tumour immunosuppressive microenvironments [99]. Here, AFP is linked to neoplasm.